Cooperative Agreement 2507825
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Palo Alto, CA 94306, USA
Similar Awards
- This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
- This Project Grant award from the National Science Foundation (NSF) under its Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Tectaria Bio LLC to engineer cell lines with activated proteasomes for increased biomanufacturing efficiency. The project aims to test the feasibility and application of a novel technology to significantly increase the protein production capabilities of cell lines used in the manufacture of biologics, gene therapies, and vaccines....
- This National Science Foundation (NSF) Cooperative Agreement award, funded under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program, will support the development and commercialization of a cost-effective peptide production platform by the small business Oakgrove Bio LLC. The $1,000,000 project aims to scale-up a recombinant technology that will dramatically decrease the cost of manufacturing peptides, which have significant potential applications ranging from antimicrobials...
- This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) aims to advance a novel vaccine platform to develop engineered vaccines that provide longer-lasting protection against infectious diseases. The $304,438 award to Nitro Biosciences Inc. will be used to overcome immune imprinting, a limitation in vaccine development where prior exposure to pathogens biases immune responses away from protective targets. The...
- This Cooperative Agreement award, with a total funding of $1,250,000.00 over a period from June 1, 2025 to May 31, 2027, was provided by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project aims to develop a novel platform technology for the scalable generation of high-quality, tumor-targeted induced naïve T cells for off-the-shelf anti-cancer immunotherapies. The key product to be delivered is a proprietary method to...
- This Cooperative Agreement award, funded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, supports the development of a novel platform for protein engineering and production using a hybrid in-vivo, in-vitro, and in-silico approach. The $2,808,001 project, executed by Caravel Bio, Inc., aims to overcome the high costs and scalability challenges of cell-free biosynthesis through the integration of four advanced technologies:...
- This $274,797 National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Deepseq.ai LLC supports the development of an AI-driven platform to accelerate the identification of highly developable single-domain antibodies for drug discovery. The proposed work aims to create a multimodal AI model capable of rapidly screening large libraries to generate lead molecules with favorable binding affinity, stability, and manufacturability. This project...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Pumpkinseed Technologies Inc. for $353,204 supports the development and demonstration of a novel technology called Cell-MAPP. The goal of this Phase I SBIR project is to create the first system capable of continuously monitoring the state transitions of individual T cells in response to antigen exposure. Cell-MAPP will utilize antigen-multimer barcoding and single-cell TCR sequencing to connect...
- This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop an "Adaptive Multi-Targeted Priming for Host-Pathogen Transcriptomics" platform. The $304,995 project, awarded to Multitarga LLC, seeks to enhance the sensitivity and specificity of RNA sequencing assays for detecting low-abundance pathogen transcripts amidst host background RNA. The technology, referred to as...
- This $305,000 STTR Phase I Project Grant awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program aims to develop an ultra-sensitive biosensor capable of protein analysis at single-molecule resolution. The biosensor consists of a nanopatterned chip with a proprietary scaffold material that binds and immobilizes molecular targets, which are then detected using surface-enhanced Raman spectroscopy (SERS). This innovation seeks...